Clinical trials: Pancreas Tumor
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
BATs Treatment for Pancreatic Cancer, Phase Ib/II
This protocol will confirm toxicities and estimate the clinical efficacy of combining anti-CD3 x anti-EGFR bispecific antibody (EGFRBi) armed activated T cells (EGFR BATs) given to patients with locally advanced or metastatic…
- Trial name
- NCT03269526
- Testing
- EGFR BATs after standard of care chemo
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Virginia
Cancer, Solid Tumor
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
This study will evaluate safety, pharmacodynamics and biomarkers of subcutaneous (SC) DK210(EGFR) given as monotherapy and in combination with immunotherapy, chemotherapy or radiation.
- Conditions
- Cancer, Solid Tumor, Colorectal Cancer, Pancreas Cancer
- Trial name
- NCT05704985
- Testing
- DK210 (EGFR), Radiation therapy, Immune checkpoint blockers
- Where
- 7 sites in United States
- Volunteers
- 39 people
- Sponsor
- DEKA Biosciences
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms
A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface
This study is open to adults with advanced solid tumors whose previous cancer treatment was not successful. People can participate if their tumor has the B7-H6 marker or if they have colorectal cancer.
- Trial name
- NCT04752215
- Testing
- BI 765049, ezabenlimab
- Where
- 14 sites in United States, Canada
- Volunteers
- 67 people
- Sponsor
- Boehringer Ingelheim
Pancreatic Cancer, Patient Reported Outcome Measures
Patient Reported Outcomes Measures to Predict Pancreatic Surgery Outcomes
This is a prospective single-center observational study with the mail objective to identify specific subgroups of patients planned for pancreatic resection, at high risk for postoperative morbidity and impaired recovery through…
- Conditions
- Pancreatic Cancer, Patient Reported Outcome Measures, Quality of Life, Pancreatectomy
- Trial name
- PRO-PANC1 (NCT04431076)
- Where
- Italy
- Volunteers
- 560 people
- Sponsor
- Massimo Falconi
Pancreatic Neoplasm
Delayed Gastric Emptying After Pancreatic Surgery
Delayed gastric emptying (DGE) is a common complication of pancreatic surgery. Once it occurs, it often affects the patient's postoperative quality of life and may even delay subsequent necessary treatments, such as adjuvant…
- Trial name
- NCT07382791
- Testing
- pancreatectomy
- Where
- Taiwan
- Volunteers
- 3,500 people
- Sponsor
- National Taiwan University Hospital
Metastatic Pancreatic Cancer
Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
This clinical trial is an open label Phase II study of the combination of intravenously administered SGT-53 and gemcitabine/nab-paclitaxel in patients with metastatic pancreatic cancer.
- Trial name
- NCT02340117
- Testing
- SGT-53, nab-paclitaxel, Gemcitabine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- SynerGene Therapeutics, Inc.
Pancreatic Neoplasms, Rectal Neoplasms
Blue and Amber Light Exposure in Patients With Rectal and Pancreatic Cancer
This study will evaluate light therapy used in combination with standard therapies for pancreatic and rectal cancer. Participants will receive chemotherapy, radiation, and surgical treatments identical to that they had not been…
- Trial name
- NCT06164691
- Testing
- Blue light, Amber light, Ambient White Light
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Matthew Neal MD
Serum Uric Acid
Whether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer
This retrospective study aims to analyze the impact of postoperative changes in serum uric acid (SUA) levels on the prognosis of patients undergoing pancreatic cancer resection.
- Trial name
- NCT07091526
- Testing
- serum uric acid test
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Recurrent
En Bloc Resection of the Liver and Pancreas With a "Non-touch" Technique Followed by Liver Transplantation to Improve the Overall Survival in Patients With Non-resectable Hilar Cholangiocarcinoma Beyond the Mayo Clinic Transplant Criteria
Surgery for hilar cholangiocarcinoma (phCCA) remains a significant challenge. The minority of patients who are eligible for resection are exposed to high procedure-related morbidity and mortality, and despite apparent R0…
- Conditions
- Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Recurrent, Liver Transplantation
- Trial name
- SURE-LT (NCT06850753)
- Testing
- Liver transplantation after en bloc resection of the liver and pancreas
- Where
- Norway
- Volunteers
- 15 people
- Sponsor
- Oslo University Hospital
Metastatic Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
This phase I/II trial is designed to efficiently identify the regimen limiting toxicity (RLT) and recommended phase 2 dose (RP2D) for the combination of the immunotherapeutic agent indoximod when administered in combination with…
- Trial name
- NCT02077881
- Testing
- Nab-Paclitaxel, Gemcitabine, Indoximod
- Where
- 11 sites in United States
- Volunteers
- 157 people
- Sponsor
- NewLink Genetics Corporation
Pancreatic Adenocarcinoma
Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer
The purpose of this study is to assess the feasibility and efficacy outcomes of neoadjuvant modified FOLFIRINOX and postoperative gemcitabine in patients with borderline resectable pancreatic cancer.
- Trial name
- NCT02749136
- Testing
- Preoperative modified FOLFIRINOX and postoperative gemcitabine
- Where
- South Korea
- Volunteers
- 44 people
- Sponsor
- Asan Medical Center
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery
This phase I trial studies the side effects and best dose of radiosurgery boost following chemoradiation in treating patients with locally advanced pancreatic cancer that may or may not be removed by surgery.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT01739439
- Testing
- gemcitabine hydrochloride, hyperfractionated radiation therapy, intensity-modulated radiation therapy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Fox Chase Cancer Center
Pancreatic Cancer, Common Bile Duct Diseases
A Multicenter Prospective Randomized Controlled Study of RPD Versus LPD
laparoscopic pancreaticoduodenectomy(LPD) and Robot Pancreaticoduodenectomy (RPD), as two minimally invasive methods of pancreaticoduodenectomy(PD), have obvious advantages over traditional open pancreaticoduodenectomy(OPD) in…
- Conditions
- Pancreatic Cancer, Common Bile Duct Diseases, Periampullary Carcinoma
- Trial name
- NCT05755607
- Testing
- laparoscopic pancreaticoduodenectomy, Robot Pancreaticoduodenectomy
- Volunteers
- 200 people
- Sponsor
- The First Affiliated Hospital of University of South China
Pancreatic Adenocarcinoma
Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP
The effect of neoadjuvant chemotherapy for pancreatic cancer was gradually established. However it has been not clarified which regimen of neoadjuvant treatment for pancreatic cancer is the best.
- Trial name
- NCT05268692
- Testing
- GS, GnP
- Where
- Japan
- Volunteers
- 500 people
- Sponsor
- Kochi University
Breast Carcinoma, Colon Carcinoma
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
This phase I trial studies a new imaging technique called FAPi PET/CT to determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulate in normal and cancer tissues in patients with non-prostate cancer.
- Conditions
- Breast Carcinoma, Colon Carcinoma, Esophageal Carcinoma, Gastric Carcinoma
- Trial name
- NCT04147494
- Testing
- Computed Tomography, Gallium Ga 68 FAPi-46, Gallium Ga 68-labeled PSMA-11
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Advanced Solid Tumor, Lymphoma
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study.
- Conditions
- Advanced Solid Tumor, Lymphoma, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT04106167
- Testing
- Allogeneic natural killer (NK) cell
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Fate Therapeutics
Metastatic Pancreas Adenocarcinoma
Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer
The purpose of this study is to learn about the safety and potential benefit of metronomic 5-fluorouracil in combination with nab®1-paclitaxel, bevacizumab, leucovorin, and oxaliplatin in treating patients with metastatic…
- Trial name
- FABLOx (NCT02620800)
- Testing
- 5FU, nab-paclitaxel, bevacizumab
- Where
- 7 sites in United States
- Volunteers
- 12 people
- Sponsor
- Celgene
Breast Cancer, Colon Cancer
CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors
Background: The p53 gene normally helps to stop cancer cells from growing. However, when the p53 gene is mutated or damaged, cancer cells may grow unchecked.
- Conditions
- Breast Cancer, Colon Cancer, Pancreatic Cancer, Sarcoma
- Trial name
- NCT01386502
- Testing
- p53: 264-272 peptide, CT-011
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
This pilot clinical trial studies 6,8-bis(benzylthio)octanoic acid in treating patients with locally advanced or metastatic pancreatic cancer.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT01839981
- Testing
- 6,8-bis(benzylthio)octanoic acid
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Wake Forest University Health Sciences
Pancreatic Adenocarcinoma (Ductal Adenocarcinoma), Early Detection of Cancer
Structured Case-Finding for Pancreatic Ductal Adenocarcinoma in Swiss Primary Care: A Feasibility Study
Pancreatic ductal adenocarcinoma (PDAC) is diagnosed at an advanced, incurable stage in more than 80% of cases in Switzerland. Certain warning signs - new-onset diabetes, unexplained weight loss, or a family history of pancreatic…
- Trial name
- PANCATCH-Pilot (NCT07723781)
- Testing
- Structured case-finding pathway (MRI/MRCP + PancreaSure biomarker assay)
- Where
- Switzerland
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Saskia Hendrich
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.